Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Founded in 1995, Depomed has successfully executed on strategy of acquiring, integrating and growing differentiated therapeutic products and building each into a strong market presence. The result is a broad portfolio of pain and neurology specialty pharmaceuticals currently comprised of five FDA-approved products. These include Gralise® for the management of Postherpetic Neuralgia (PHN), Cambia® for the acute treatment of migraine attacks, Zipsor® for the relief of mild to moderate acute pain, Lazanda® for the management of breakthrough pain in cancer patients and our most recent addition, the company’s flagship asset, the NUCYNTA® franchise. Acquired in April 2015 and re-launched in June 2015, the NUCYNTA franchise includes NUCYNTA® ER for the extended management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) and NUCYNTA® for immediate management of moderate to severe acute pain in adults. Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. The company’s Acuform technology is currently being used in four marketed drugs, including Gralise. Depomed’s successful execution on strategy and has resulted in solid product revenue growth over the past three years. Located in Newark, California in the East Bay of San Francisco, Depomed is listed on the NASDAQ market under the ticker DEPO and employs approximately 500 people, of which approximately 350 are part of the Commercial organization.
Company Growth (employees)
Newark, US
Size (employees)
490 (est)
Depomed was founded in 1995 and is headquartered in Newark, US

Key People/Management at Depomed

James A. Schoeneck

James A. Schoeneck

President and CEO

Depomed Office Locations

Depomed has an office in Newark
Newark, US (HQ)
300 7999 Gateway Blvd

Depomed Financials and Metrics

Depomed Financials

Depomed's revenue was reported to be $455.9 m in FY, 2016

Revenue (Q3, 2017)

95.4 m

Gross profit (Q3, 2017)

78 m

Gross profit margin (Q3, 2017), %


Net income (Q3, 2017)

(16 m)

EBIT (Q3, 2017)

1.2 m

Market capitalization (08-Dec-2017)

514.7 m

Cash (30-Sep-2017)

107.6 m
Depomed's current market capitalization is $514.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


134.2 m390.4 m342.7 m455.9 m

Revenue growth, %


Cost of goods sold

7.1 m15.1 m67.9 m87.4 m

Gross profit

127.1 m375.2 m274.8 m368.5 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


76.5 m67.7 m51.5 m32.2 m94.5 m104.9 m104.8 m116.7 m110.5 m90.4 m100.5 m95.4 m

Cost of goods sold

3.7 m4.7 m3.5 m3.1 m22.9 m20.9 m23.5 m21 m20.2 m17.8 m19.7 m17.4 m

Gross profit

72.8 m63.1 m48 m29.1 m71.6 m83.9 m81.2 m95.7 m90.3 m72.7 m80.7 m78 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


244.7 m488.7 m101.1 m117.7 m

Accounts Receivable

11.5 m27 m71.1 m102.1 m


10.1 m8.5 m10.5 m13 m

Current Assets

337 m617.6 m309 m306.2 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


195.3 m211.1 m546.7 m52.8 m94.1 m107.5 m182 m87.8 m90.4 m187.8 m113.2 m107.6 m

Accounts Receivable

12.8 m17.3 m20 m23.5 m59.8 m68.4 m69.9 m79.5 m87 m67.5 m78.3 m77.2 m


8.5 m7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m12 m10.4 m10.4 m

Current Assets

313.3 m309.6 m632.5 m613.5 m232.2 m302.8 m292.6 m230.2 m260.9 m286.8 m219 m219.3 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    43.3 m131.8 m(75.7 m)(88.7 m)

    Depreciation and Amortization

    6.2 m12 m85.7 m106.8 m

    Accounts Receivable

    (7.8 m)(15 m)(44 m)(30.9 m)


    4.3 m1.7 m9.3 m(3.7 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    17.9 m12.7 m6.5 m(11.6 m)(21.7 m)(11.8 m)(20.9 m)(10.5 m)(12.9 m)(26.7 m)(53.4 m)(16 m)

    Depreciation and Amortization

    2.5 m2.5 m2.5 m26.7 m27 m27 m27 m27 m26.3 m52.7 m

    Accounts Receivable

    8.3 m17.3 m20 m23.5 m59.8 m68.4 m69.9 m79.5 m87 m34.5 m23.7 m77.2 m


    7.8 m7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m873 k490 k10.4 m
      USDY, 2017


      194.7 k

      Financial Leverage

      5.3 x
      Show all financial metrics

      Depomed Market Value History

      Depomed's Web-traffic and Trends

      Depomed News and Updates

      Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs

      Depomed is selling off the franchise that was once the center of its growth hopes, and plenty of the company's employees are leaving with it. Less than three years after shelling out $1.05 billion to acquire Nucynta ER and XR from Johnson & Johnson, the California drugmaker has licensed the meds…

      Depomed Company Life and Culture

      You may also be interested in